A Phase I Study of Immunotherapy With E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2017
At a glance
- Drugs E6 TCR (Primary) ; Aldesleukin
- Indications Cervical intraepithelial neoplasia
- Focus Adverse reactions
- 28 Jul 2017 Status changed from not yet recruiting to recruiting.
- 27 Jul 2017 Planned initiation date changed from 1 aug 2017 to 2 Aug 2017.
- 26 Jul 2017 Planned initiation date changed from 31 Jul 2017 to 1 Aug 2017.